Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387127 · ClinicalTrials.gov registry record · Phase 2
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT00387127 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 67 participants.
The verdict
NCT00387127, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
This is a phase II study comparing the effects of lapatinib versus placebo when administered concurrently with cisplatin and radiotherapy followed by 1 year monotherapy with lapatinib or placebo. The study is designed to evaluate and compare the two treatment groups with respect to complete response rate at 6 months following chemoradiation completion.
Interventions
- DRUG Lapatinib oral tablets
- DRUG radiotherapy
- DRUG cisplatin chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2006-11 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387127
The ClinicalTrials.gov registry entry for NCT00387127 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lapatinib oral tablets is the first listed.
NCT00387127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387127 about?
NCT00387127 is a clinical study titled "Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer". This is a phase II study comparing the effects of lapatinib versus placebo when administered concurrently with cisplatin and radiotherapy followed by 1 year monotherapy with lapatinib or placebo. The study is designed to evaluate and compare the two treatment groups with respect to complete response...
What is the current status of trial NCT00387127?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2006-11. Estimated completion is 2014-01.
What interventions are being tested in trial NCT00387127?
The interventions under investigation include: Lapatinib oral tablets (DRUG), radiotherapy (DRUG), cisplatin chemotherapy (DRUG).
Who is sponsoring clinical trial NCT00387127?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.